PPD (PPDI) Confirms Takeda Receives FDA Complete Response for Alogliptin
More News related to PPDI
- PPD Launches New Global Biostatistics Technology Infrastructure
- Notable Mergers and Acquisitions of the Day 11/30: SYK, PPDI, CAT, VNR, CBE/FSS
- PPD (PPDI) Completes $77M Cash Acquisition of BioDura
- PPD Completes Acquisition of BioDuro
- PPD, Inc. (PPDI) Agrees to Acquire BioDuro
PPD, Inc. (NASDAQ: PPDI) announced that Takeda Pharmaceutical Company Limited issued a news release reporting that Takeda Global Research & Development Center, Inc., its wholly-owned U.S. subsidiary, has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding its new drug application (NDA) for alogliptin.
PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.26Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
